Ikaika is expanding the frontier of fibrotic treatments through the power of genetics –
Our team uncovered a novel target capable of modifying the outcome of fibrotic diseases.
We identified genetic signals that regulate muscle disease progression by combining quantitative trait loci mapping with genome-wide mapping. We established that latent TGF-β binding protein 4 (LTBP4) has a key role in modulating fibrosis deposition, as LTBP4 inhibits activation of latent transforming growth factor-β (TGF-β), a well-known regulator that promotes fibrosis formation.
Company Details
Ikaika Therapeutics Questions
Ikaika Therapeutics's website is http://www.ikaikatherapeutics.com
Ikaika Therapeutics's LinkedIn profile is https://www.linkedin.com/company/ikaika-therapeutics
Ikaika Therapeutics has
4 employees.
View email and phone details for 4
employees at Ikaika Therapeutics.
Ikaika Therapeutics's industry is
Biotechnology
Ikaika Therapeutics's top competitors are
Grove Biopharma, Inc.,
Dimension Bio,
Immpro,
Avandra Imaging,
Nspire Co,
Qral Ventures,
Yobee,
Syenex,
Acorn Genetics,
Amphix Bio.
Ikaika Therapeutics's categories are Biotechnology
